Accéder au contenu
Merck

A prodrug approach to improve the physico-chemical properties and decrease the genotoxicity of nitro compounds.

Current pharmaceutical design (2011-11-15)
Man Chin Chung, Priscila Longhin Bosquesi, Jean Leandro dos Santos
RÉSUMÉ

In therapeutics research, the nitro compounds are part of an important group of drugs with multiple pharmacological activities. However, in drug design, the inclusion of a nitro group in a molecule changes the physico-chemical and electronic properties and is associated with increased mutagenicity and carcinogenicity. In addition, several studies have related the relationship between the antimicrobial and/or anti-protozoal activity and the mutagenic effect to reduction of the nitro group. This work reviews the toxicity of nitro compounds and shows how the use of prodrugs can increase the biological activity and decrease the genotoxicity of nitro compounds, without any modification in nitro reduction behavior, but rather by physico-chemical improvement. Examples are given of metronidazole and nitrofurazone prodrugs.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
5-Nitro-2-furaldehyde semicarbazone, ≥97.0% (HPLC)
Supelco
Nitrofurazone, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Nitrofurazone solution, VETRANAL®, 100 μg/mL in acetonitrile, analytical standard